$1.96
4.21%
Downside
Day's Volatility :7.52%
Upside
3.45%
22.96%
Downside
52 Weeks Volatility :86.78%
Upside
82.84%
Period | Inotiv Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -51.11% | 6.5% | 0.0% |
6 Months | -39.82% | 7.1% | 0.0% |
1 Year | -71.88% | 9.8% | 0.0% |
3 Years | -93.26% | 14.2% | -20.2% |
Market Capitalization | 53.0M |
Book Value | $8.0 |
Earnings Per Share (EPS) | -2.77 |
Wall Street Target Price | 4.67 |
Profit Margin | -12.9% |
Operating Margin TTM | -35.07% |
Return On Assets TTM | -2.67% |
Return On Equity TTM | -30.12% |
Revenue TTM | 552.7M |
Revenue Per Share TTM | 21.49 |
Quarterly Revenue Growth YOY | -21.4% |
Gross Profit TTM | 157.2M |
EBITDA | 20.9M |
Diluted Eps TTM | -2.77 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.02 |
EPS Estimate Next Year | -2.59 |
EPS Estimate Current Quarter | -0.54 |
EPS Estimate Next Quarter | -0.08 |
What analysts predicted
Upside of 138.27%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 26.3M | ↑ 8.68% |
Net Income | -194.0K | ↓ 121.95% |
Net Profit Margin | -0.74% | ↓ 4.39% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 43.6M | ↑ 65.55% |
Net Income | -790.0K | ↑ 307.22% |
Net Profit Margin | -1.81% | ↓ 1.07% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 60.5M | ↑ 38.64% |
Net Income | -4.7M | ↑ 493.04% |
Net Profit Margin | -7.75% | ↓ 5.94% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 89.6M | ↑ 48.18% |
Net Income | 10.9M | ↓ 332.55% |
Net Profit Margin | 12.16% | ↑ 19.91% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 547.7M | ↑ 511.19% |
Net Income | -337.3M | ↓ 3195.57% |
Net Profit Margin | -61.58% | ↓ 73.74% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 572.4M | ↑ 4.52% |
Net Income | -105.1M | ↓ 68.83% |
Net Profit Margin | -18.37% | ↑ 43.21% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 150.5M | ↑ 0.0% |
Net Income | -243.6M | ↓ 0.22% |
Net Profit Margin | -161.92% | ↑ 0.35% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 151.5M | ↑ 0.66% |
Net Income | -9.6M | ↓ 96.05% |
Net Profit Margin | -6.36% | ↑ 155.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 157.5M | ↑ 3.96% |
Net Income | 1.8M | ↓ 119.11% |
Net Profit Margin | 1.17% | ↑ 7.53% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 140.7M | ↓ 10.62% |
Net Income | -9.7M | ↓ 625.16% |
Net Profit Margin | -6.87% | ↓ 8.04% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 135.5M | ↓ 3.72% |
Net Income | -15.4M | ↑ 59.25% |
Net Profit Margin | -11.36% | ↓ 4.49% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 119.0M | ↓ 12.15% |
Net Income | -48.1M | ↑ 212.44% |
Net Profit Margin | -40.39% | ↓ 29.03% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 31.3M | ↑ 53.15% |
Total Liabilities | 20.4M | ↑ 70.58% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 42.0M | ↑ 34.26% |
Total Liabilities | 31.3M | ↑ 53.4% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 61.6M | ↑ 46.72% |
Total Liabilities | 54.0M | ↑ 72.68% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 321.9M | ↑ 422.55% |
Total Liabilities | 216.7M | ↑ 301.37% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 962.9M | ↑ 199.17% |
Total Liabilities | 603.1M | ↑ 178.29% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 856.5M | ↓ 11.05% |
Total Liabilities | 588.0M | ↓ 2.5% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 962.9M | ↑ 0.0% |
Total Liabilities | 603.1M | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 868.7M | ↓ 9.79% |
Total Liabilities | 596.0M | ↓ 1.18% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 854.8M | ↓ 1.59% |
Total Liabilities | 579.5M | ↓ 2.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 856.5M | ↑ 0.2% |
Total Liabilities | 588.0M | ↑ 1.47% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 835.5M | ↓ 2.45% |
Total Liabilities | 581.3M | ↓ 1.14% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 815.4M | ↓ 2.41% |
Total Liabilities | 608.2M | ↑ 4.62% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.5M | ↑ 182.12% |
Investing Cash Flow | -8.1M | ↑ 2281.71% |
Financing Cash Flow | 4.9M | ↓ 680.21% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.8M | ↓ 49.04% |
Investing Cash Flow | -8.1M | ↑ 0.93% |
Financing Cash Flow | 6.2M | ↑ 25.96% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.3M | ↓ 27.41% |
Investing Cash Flow | -10.1M | ↑ 24.32% |
Financing Cash Flow | 9.6M | ↑ 55.37% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 10.7M | ↑ 733.02% |
Investing Cash Flow | -54.1M | ↑ 433.61% |
Financing Cash Flow | 198.8M | ↑ 1962.36% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.2M | ↓ 148.55% |
Investing Cash Flow | -333.7M | ↑ 517.32% |
Financing Cash Flow | 203.2M | ↑ 2.17% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 171.0K | ↑ 0.0% |
Investing Cash Flow | -15.6M | ↑ 0.0% |
Financing Cash Flow | 14.0M | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 12.8M | ↑ 7406.43% |
Investing Cash Flow | -8.4M | ↓ 46.1% |
Financing Cash Flow | -1.2M | ↓ 108.29% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.7M | ↓ 71.22% |
Investing Cash Flow | -4.5M | ↓ 46.56% |
Financing Cash Flow | -1.0M | ↓ 10.17% |
Sell
Neutral
Buy
Inotiv Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Inotiv Inc | 17.16% | -39.82% | -71.88% | -93.26% | -88.33% |
![]() Idexx Laboratories, Inc. | -3.67% | -10.34% | -15.37% | -31.35% | 65.77% |
![]() Agilent Technologies Inc. | 1.42% | 3.05% | 5.07% | -10.16% | 94.22% |
![]() Thermo Fisher Scientific, Inc. | 6.51% | 8.62% | 3.5% | 12.36% | 106.99% |
![]() Danaher Corp. | 6.51% | 15.92% | 1.97% | -6.92% | 89.83% |
![]() Iqvia Holdings Inc. | 10.0% | 7.5% | 0.14% | -6.07% | 45.29% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Inotiv Inc | NA | NA | NA | -4.02 | -0.3 | -0.03 | NA | 8.0 |
![]() Idexx Laboratories, Inc. | 45.67 | 45.67 | 4.75 | 11.06 | 0.72 | 0.23 | NA | 18.93 |
![]() Agilent Technologies Inc. | 31.63 | 31.63 | 2.7 | 5.2 | 0.21 | 0.08 | 0.01 | 21.31 |
![]() Thermo Fisher Scientific, Inc. | 35.72 | 35.72 | 2.81 | 21.71 | 0.14 | 0.05 | 0.0 | 120.87 |
![]() Danaher Corp. | 48.76 | 48.76 | 3.13 | 6.99 | 0.08 | 0.04 | 0.0 | 68.92 |
![]() Iqvia Holdings Inc. | 30.13 | 30.13 | 1.33 | 11.19 | 0.23 | 0.05 | NA | 36.83 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Inotiv Inc | Buy | $53.0M | -88.33% | NA | -12.9% |
![]() Idexx Laboratories, Inc. | Buy | $38.8B | 65.77% | 45.67 | 23.26% |
![]() Agilent Technologies Inc. | Buy | $38.9B | 94.22% | 31.63 | 18.84% |
![]() Thermo Fisher Scientific, Inc. | Buy | $219.4B | 106.99% | 35.72 | 14.2% |
![]() Danaher Corp. | Buy | $191.9B | 89.83% | 48.76 | 17.83% |
![]() Iqvia Holdings Inc. | Buy | $42.3B | 45.29% | 30.13 | 9.39% |
Insights on Inotiv Inc
Revenue is down for the last 4 quarters, 157.46M → 119.03M (in $), with an average decrease of 8.8% per quarter
Netprofit is down for the last 4 quarters, 1.84M → -48.07M (in $), with an average decrease of 299.0% per quarter
In the last 1 year, Agilent Technologies Inc. has given 5.1% return, outperforming this stock by 77.0%
In the last 3 years, Inotiv Inc has experienced a drawdown of -93.3%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 83.1%
Vanguard Group Inc
Millennium Management LLC
Ameriprise Financial Inc
Kpp Advisory Services LLC
Goldman Sachs Group Inc
Geode Capital Management, LLC
*we are a cro and lab instrumentation provider* basi is a drug discovery and development services company with the energy and expertise to help you with your drug development project. we provide world-class research to the global pharmaceutical industry. our services include preclinical toxicology, early in vivo pk, bioanalysis and a full range of pharmaceutical analysis services. basi also manufactures innovative scientific instruments including the culex® automated in vivo sampling system which can collect blood, bile, microdialysates, activity behavior, telemetry data and more from awake, freely-moving subjects. we are known for our scientific expertise, responsiveness to clients, exemplary regulatory record, and helping our clients meet key milestones on time.
Organization | Inotiv Inc |
Employees | 1955 |
CEO | Mr. Robert W. Leasure Jr. |
Industry | Healthcare |